<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Omega</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id>
    <journal-id journal-id-type="publisher-id">ao</journal-id>
    <journal-id journal-id-type="coden">acsodf</journal-id>
    <journal-title-group>
      <journal-title>ACS Omega</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2470-1343</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9025992</article-id>
    <article-id pub-id-type="doi">10.1021/acsomega.1c07144</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ELIXIR-A: An Interactive Visualization Tool for Multi-Target
Pharmacophore Refinement</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Wang</surname>
          <given-names>Haoqi</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Mulgaonkar</surname>
          <given-names>Nirmitee</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1176-1027</contrib-id>
        <name>
          <surname>Pérez</surname>
          <given-names>Lisa M.</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7692-2170</contrib-id>
        <name>
          <surname>Fernando</surname>
          <given-names>Sandun</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Biological
and Agricultural Engineering Department, <institution>Texas A&amp;M University</institution>, College Station, Texas 77843, <country>United States</country></aff>
      <aff id="aff2"><label>‡</label>High
Performance Research Computing, <institution>Texas A&amp;M
University</institution>, College
Station, Texas 77843, <country>United States</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>sfernando@tamu.edu</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>05</day>
      <month>04</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>19</day>
      <month>04</month>
      <year>2022</year>
    </pub-date>
    <volume>7</volume>
    <issue>15</issue>
    <fpage>12707</fpage>
    <lpage>12715</lpage>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>12</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>03</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0009" id="ab-tgr1"/>
      </p>
      <p>Pharmacophore modeling
is an important step in computer-aided drug
design for identifying interaction points between the receptor and
ligand complex. Pharmacophore-based models can be used for <italic>de novo</italic> drug design, lead identification, and optimization
in virtual screening as well as for multi-target drug design. There
is a need to develop a user-friendly interface to filter the pharmacophore
points resulting from multiple ligand conformations. Here, we present
ELIXIR-A, a Python-based pharmacophore refinement tool, to help refine
the pharmacophores between multiple ligands from multiple receptors.
Furthermore, the output can be easily used in virtual pharmacophore-based
screening platforms, thereby contributing to the development of drug
discovery.</p>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ao1c07144</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ao1c07144</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Drug discovery and
development is a complex, time-consuming, and
expensive process. Computer-aided drug design approaches have the
potential to accelerate this process cost-effectively when compared
to the laborious traditional compound screening methods. Existing
computational techniques include quantitative structure–activity
relationship (QSAR), molecular docking-based high-throughput, and
pharmacophore-based virtual compound screening. In the usual virtual
drug discovery process, molecular docking, pharmacophore models, and
3D QSAR models are often used in combination.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref3">3</xref></sup> Existing QSAR
or docking approaches do not have the capability of pharmacophore
refinement, and thus, there is a need for a technique for refining
pharmacophores to identify the best set of pharmacophores for the
modern drug discovery process.</p>
    <p>The pharmacophore concept was
introduced by Ehrlich in early 1909.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> A
pharmacophore is an ensemble of steric and
electronic features that is necessary to ensure optimal supramolecular
interactions with a specific biological target structure and to trigger
(or to block) its biological response.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Pharmacophores describe specific ligand–receptor interactions
as a generalized pattern. The first 3D pharmacophore screening software
was developed by Gund in 1977.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Pharmacophore
modeling approaches can be broadly classified as ligand-based or receptor-based.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Software programs such as LigandScout,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> DISCO,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> GASP,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> GALAHAD,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> HipHop,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> HypoGen,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> MOE (Chemical
Computing Group, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemcomp.com">https://www.chemcomp.com</uri>), PharmaGist,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> MolAlign,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and PHASE<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> have
been developed to construct ligand-based pharmacophore models. Their
performance differs based on the efficiency of the algorithm to handle
ligand flexibility and alignment and requires a set of pharmacologically
active ligands.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> On the contrary, receptor-based
methods, such as GBPM,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> LigandScout,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Pharmit,<sup><xref ref-type="bibr" rid="ref18">18</xref>−<xref ref-type="bibr" rid="ref20">20</xref></sup> PyRod,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and ZINCPharmer,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> analyze the receptor–ligand
complex structures to isolate essential pharmacophoric features.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> A 2D pharmacophore fingerprint is a form of
a binary code that contains pharmacophore properties.<sup><xref ref-type="bibr" rid="ref24">24</xref>−<xref ref-type="bibr" rid="ref27">27</xref></sup> These pharmacophore fingerprints containing molecular fragments
have been applied with multiple artificial intelligence-related models
such as PTML,<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Pharmacoprint,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> and Pharm-IF.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></p>
    <p>In situations
where ligands are not known for the target receptor,
methods such as CavityPlus,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> GRID,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> HS-Pharm,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Pocket
version 4.0,<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Shaper2,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> GRAIL,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> and SuperStar<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> have been developed to identify hotspots (highly probable
ligand binding sites) on the receptor. Druggability simulations (molecular
dynamics simulations conducted in the presence of drug-like organic
molecules) assess ligand hotspots while maintaining receptor flexibility.
Tools like SILCS-Pharm from the Mackerell lab<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> and Pharmmaker from the Bahar lab<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> have
been developed to extract pharmacophore features from druggability
simulations. However, there is a need for a systematic tool that analyzes
and compares multiple pharmacophore models irrespective of their method
of construction.</p>
    <p>Here, we present the Enhanced Ligand Exploration
and Interaction
Recognition Algorithm (ELIXIR-A), an open-source, user-friendly application
that serves the purpose of both pharmacophore modeling and pharmacophore
mapping. ELIXIR-A is a Python-based application that can import pharmacophore
models created in Visual Molecular Dynamics (VMD),<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> as well as manual coordinate input from any other platform.
In addition, the output files from ELIXIR-A can be easily visualized
in VMD<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> and can be exported to pharmacophore-based
virtual screening platforms like Pharmit.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></p>
  </sec>
  <sec id="sec2">
    <title>Methodology</title>
    <p>ELIXIR-A was developed to unify and simplify
the interaction data
from multiple pharmacophore models. This tool can accept two sets
of pharmacophore models created directly by a pharmacophore generating
platform. For example, the platform can accept ligand-based pharmacophore
models created directly by Pharmit as the input. ELIXIR-A is developed
on the modern 3D data processing library Open3D<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> to include the algorithms of fast global registration<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> and colored point cloud registration (colored
ICP)<sup><xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). ELIXIR-A initially prepares each pharmacophore point
represented as a point cloud with its radius, and the pharmacophores
are color coded into different types. Then, ELIXIR-A aligns two structures
and calculates the initial transformation matrix based on their geometric
properties only. Finally, the two pharmacophore clouds are superpositioned
with their geometric and pharmacophore type information, and the overlaid
pharmacophore point is refined with matched points.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Flow diagram of the computational
procedures of ELIXIR-A.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0002" id="gr1" position="float"/>
    </fig>
    <sec id="sec2.1">
      <title>Pharmacophore Point Clouds</title>
      <p>As a shape similarity approach,
ELIXIR-A takes pharmacophore points and applies each of them to a
three-dimensional volume with a point cloud. Each pharmacophore type
consists of 1000 uniformly distributed points in a sphere. The radius
of the pharmacophore cloud is defined in the occupancy category of
the pdb file. The pharmacophore type is marked with three characters
in the residue name category (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.1c07144/suppl_file/ao1c07144_si_001.pdf">Table S1</ext-link>).
Throughout the complete analysis, the Biopandas framework is used
to handle the point cloud data.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup></p>
    </sec>
    <sec id="sec2.2">
      <title>Global
Registration with RANSAC Iteration</title>
      <p>The first
alignment is the global alignment with features. Two pharmacophore
point clouds are treated with the same process to calculate a vector
of descriptors called the Fast Point Feature Histogram (FPFH).<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> FPFH is a 33-dimensional vector that describes
the geometric characteristics and principles for a point. The FPFH
vector can search points with similar features.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> As ELIXIR-A attempts to align pharmacophore sites from
multiple ligands or receptors, there may be distinct differences between
some areas of the clouds considered as “noise”. It is
known from experience that substantial noise levels can affect the
alignment of point clouds with FPFH matching. To enhance the search
of the FPFH matching algorithm, the random sample consensus (RANSAC)
algorithm, proposed by Fischler and Bolles,<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> is included in the registration process. RANSAC can estimate parameters
of a mathematical model from a set of observed data with “noise”.
The global registration process calculates a preliminary rigid rotation
and transformation matrix with their geometric characteristics. A
fitness score will be given to evaluate this initial transformation.</p>
    </sec>
    <sec id="sec2.3">
      <title>Colored ICP</title>
      <p>The second alignment is the local ICP alignment
with pharmacophore features. The pharmacophore alignment utilizing
colored features is inspired by the alignment of the red, green, blue
model (RGB) image and its corresponding depth image by Park et al.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> In general, the colored ICP algorithm extends
the color vector as the extra dimension of the point coordinate data.
The standard ICP algorithm will repeat the transformation of matrices
to find the minimum square distance between two clouds. In comparison,
the colored ICP algorithm will find the best fit of the extended paired
matrices with the pharmacophore “color” information
for each point. ELIXIR-A uses a slightly different number of iterations,
fitness values, and root-mean-square deviation (RMSD) values from
the default to optimize pharmacophore alignment. ELIXIR-A also supports
the user adjustment of these critical parameters to obtain a more
appropriate fit for the transformation.</p>
    </sec>
    <sec id="sec2.4">
      <title>Pharmacophore Refinement</title>
      <p>After applying preliminary
global transformation and local colored ICP transformation from the
point cloud superposition to the first pharmacophore input, two pharmacophore
points are partially overlapped. It is necessary to remove the nonoverlapped
pharmacophore using the refinement algorithm. The algorithm first
creates two 3′ N matrices A and B for two groups of pharmacophore
datasets. A is defined as the transforming source group, and B is
defined as the fixed target. The Euclidean distance for each point
in group A to find the corresponding point in group B is calculated.
Then, the Euclidean distance for each point in group B to find the
corresponding point in group A is evaluated. In each group, if there
is no corresponding point within the threshold distance, this point
will be considered irrelevant and removed from the group. According
to the definition of the pharmacophore, it is possible for different
types of pharmacophores to exist in superposition; therefore, this
refinement only calculates the geometric properties and does not consider
the color parameters of the pharmacophore. The alignment of the two
refined pharmacophore points will be visualized as the van der Waals
surface (vdW) in VMD. These files will be saved in the same path as
the two input pharmacophore files<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_m001" position="anchor"/></disp-formula></p>
    </sec>
    <sec id="sec2.5">
      <title>Fitness Score
Function</title>
      <p>ELIXIR-A uses a fitness value
to evaluate the effectiveness of the transformation for both alignment
algorithms. Fitness is calculated using the formula below to find
the volume ratio of overlap. The higher the fitness value, the better
the alignment performance<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_m002" position="anchor"/></disp-formula></p>
    </sec>
    <sec id="sec2.6">
      <title>Benchmark Compound Validation</title>
      <p>To
validate the efficiency
of the pharmacophore refinement algorithm, a molecular dataset consisting
of active inhibitors and inactive decoys targeting specific protein
receptors was designed to reduce the testing bias. All the pharmacophore
models were screened on the Pharmit platform, and the Directory of
Useful Decoys (DUD-e) dataset was used as the small molecule library.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> The benchmark receptors were human immunodeficiency
virus type 1 protease (HIVPR), acetylcholinesterase (ACES), and cyclin-dependent
kinase 2 (CDK2). These proteins are in different protein families
(protease, esterase, and kinase). The feature “shared pharmacophores”
in the LigandScout 4.4 Demo version was used as the comparison pharmacophore
refinement algorithm in this study. Schrödinger Phase (release
2020–1) was used as another comparison software. The E-Pharmacophore
plugin prepared the pharmacophore model under the receptor–ligand
complex mode. The hypothesis alignment plugin was used for pharmacophore
alignment with 2.0 Å feature matching tolerance and three minimum
number of matching features. The overlapped pharmacophore was selected
by manual inspection.</p>
      <p>The molecular weight (<italic>M</italic><sub>W</sub>), octanol–water partition coefficient (log<italic>P</italic>), and the total polar surface area (TPSA) were used to
compare physicochemical properties between the screened active and
decoy molecules. These physicochemical properties were calculated
by open babel v2.4.0.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The properties
were compared using the two-tailed Student’s <italic>t</italic> test.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> The equality of two variances
was given by the F-test.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> The significance
level was set to 0.05 (α = 0.05).</p>
    </sec>
    <sec id="sec2.7">
      <title>Enrichment Factor</title>
      <p>Enrichment factors (EF) of the pharmacophore-based
virtual screening represent the ability of the pharmacophore model
to find true positive active inhibitors in the database in contrast
to random selection. EF can be calculated using the ratio of the active
inhibitors in the screened subgroup over the ratio of active inhibitors
in the whole database. The higher the EF value, the better the pharmacology
model performance<disp-formula id="ueq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_m003" position="anchor"/></disp-formula></p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results</title>
    <sec id="sec3.1">
      <title>Configuration</title>
      <p>ELIXIR-A is designed as a GUI plugin
based on VMD. The script itself is pre-configured. The first step
is to install VMD and then edit the startup files in the VMD folder.
The physical system requirements for ELXIR-A will not exceed the requirements
of the VMD software itself. Once the setup files have been updated,
the ELXIR-A folder must be placed in the VMD TCL plugin directory.
The ELIXIR-A option can be found under the top menu. A Python environment
is required to run the script for ELIXIR-A. The package was tested
in cPython 3.8.8 with the following packages (Numpy==1.20.1; Open3D==0.13.0;
Biopandas==0.2.9.dev0; and Matplotlib==3.3.4).<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref54">54</xref></sup></p>
    </sec>
    <sec id="sec3.2">
      <title>Execution of
Pharmacophore Alignment Jobs</title>
      <p>ELIXIR-A
provides two ways to introduce the pharmacophore information to the
GUI (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The
user can choose to pre-edit the text file with the “.pdb”
extension via “Import pdb file:”, or directly use the
Pharmit saved session file “.json”, which is the same
as the pre-edited pdb file. The guidelines for the text files are
described in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.1c07144/suppl_file/ao1c07144_si_001.pdf">Table S2</ext-link>.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>ELIXIR-A interface. The
target receptor can be loaded to visualize
the pharmacophore–receptor interactions. According to different
data sets, the default parameters can be optimized to improve the
alignment performance.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0003" id="gr2" position="float"/>
      </fig>
    </sec>
    <sec id="sec3.3">
      <title>Visualization of Results</title>
      <p>The first pharmacophore cluster
is recommended as the first primary site. The second cluster is interactively
rotated and transformed to retrieve the conformation that best fits
the primary site. Once all the data are prepared in the GUI, the “submit”
button can be used to analyze the pharmacophore points’ alignment.
This demonstration used ELIXIR-A to find refined structure-based pharmacophores
from HIVPR (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). These models were prepared in Pharmit and visualized in Maestro.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> The receptor HIVPR is an essential enzyme of
HIV replication. The active site of HIVPR was at the core of the dimerization
interface (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). The pharmacophores of the ligand(s) were extracted from Pharmit
Engine (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> In the VMD OpenGL Display window, two groups
of vdW spheres are represented as pharmacophores after the ELXIR-A
alignment. The transformed pharmacophores were presented with solid
spheres. The fixed pharmacophores were presented as transparent spheres.
The ligand regarding the fixed pharmacophores is also shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> left. The initial
transformation has 15.39% of point cloud overlap, and the colored
ICP improved the overlay by up to 65.66%. After refinement, two separate
pharmacophore spheres in each group did not overlap and were therefore
removed. A total of eight pharmacophores shared the superposition
space, and this result can be used for further drug discovery. In
addition to the HIVPR, the use of similarity refinement for the analysis
of two other types of proteins is also applied in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Pharmacological description
of the two HIVPR in the crystal structure
in complex with inhibitors.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0004" id="gr3" position="float"/>
      </fig>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Structure-based
pharmacophore refinement between HIVPR-inhibitor
complexes utilizing ELIXIR-A. The transformed pharmacophores are presented
with solid spheres. The fixed pharmacophores are presented using transparent
spheres.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0005" id="gr4" position="float"/>
      </fig>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>ELIXIR-A Aligned
Pharmacophore Cluster
Selection</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="center"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th colspan="2" align="center">best fitness
score<hr/></th>
              <th style="border:none;" align="center"> </th>
            </tr>
            <tr>
              <th style="border:none;" align="center">PDB ID<xref rid="t1fn1" ref-type="table-fn">a</xref></th>
              <th style="border:none;" align="center">target</th>
              <th style="border:none;" align="center">ligand ID<xref rid="t1fn2" ref-type="table-fn">b</xref></th>
              <th style="border:none;" align="center">initial points</th>
              <th style="border:none;" align="center">refined points</th>
              <th style="border:none;" align="center">RMSD (Å)</th>
              <th style="border:none;" align="center">global registration</th>
              <th style="border:none;" align="center">colored ICP</th>
              <th style="border:none;" align="center">ref</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">1YT9</td>
              <td rowspan="2" style="border:none;" align="center">HIVPR</td>
              <td style="border:none;" align="left">OIS</td>
              <td style="border:none;" align="left">11</td>
              <td style="border:none;" align="left">8</td>
              <td rowspan="2" style="border:none;" align="center">0.267</td>
              <td rowspan="2" style="border:none;" align="center">15.39%</td>
              <td rowspan="2" style="border:none;" align="center">65.66%</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref57">57</xref>)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">2FDE</td>
              <td style="border:none;" align="left">385</td>
              <td style="border:none;" align="left">9</td>
              <td style="border:none;" align="left">8</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref58">58</xref>)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">1Q84</td>
              <td rowspan="2" style="border:none;" align="center">ACES</td>
              <td style="border:none;" align="left">TZ4</td>
              <td style="border:none;" align="left">14</td>
              <td style="border:none;" align="left">5</td>
              <td rowspan="2" style="border:none;" align="center">0.256</td>
              <td rowspan="2" style="border:none;" align="center">14.65%</td>
              <td rowspan="2" style="border:none;" align="center">42.15%</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref59">59</xref>)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">2CEK</td>
              <td style="border:none;" align="left">N8T</td>
              <td style="border:none;" align="left">7</td>
              <td style="border:none;" align="left">3</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref60">60</xref>)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">6INL</td>
              <td rowspan="2" style="border:none;" align="center">CDK2</td>
              <td style="border:none;" align="left">AJR</td>
              <td style="border:none;" align="left">7</td>
              <td style="border:none;" align="left">4</td>
              <td rowspan="2" style="border:none;" align="center">0.287</td>
              <td rowspan="2" style="border:none;" align="center">30.612%</td>
              <td rowspan="2" style="border:none;" align="center">31.82%</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref61">61</xref>)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">4EOR</td>
              <td style="border:none;" align="left">4SP</td>
              <td style="border:none;" align="left">6</td>
              <td style="border:none;" align="left">4</td>
              <td style="border:none;" align="center">(<xref ref-type="bibr" rid="ref62">62</xref>)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t1fn1">
            <label>a</label>
            <p>The protein complexes were downloaded
from the Protein Data Bank (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org">https://www.rcsb.org</uri>).</p>
          </fn>
          <fn id="t1fn2">
            <label>b</label>
            <p>These ligands are the
local substrates
corresponding to the protein complexes. Detailed information on the
ligands is available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/ligand/">https://www.rcsb.org/ligand/</uri>(ligand ID).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec3.4">
      <title>Benchmark Compound
Validation</title>
      <p>A benchmark compound
study was used to validate the effectiveness of the module in generating
enriched screened molecules using refined pharmacophores. For comparison,
the same analysis was carried out for the benchmark compounds using
the two software packages that possess pharmacophore alignment modules,
LigandScout and Phase, which were accessible to the researchers. We
used three targets for benchmarking after considering 11 data sets
that are freely available for validation in the Zinc15 database, which
also would give positive results for all three screening platforms,
i.e., ELIXIR-A, Phase, and LigandScout. The usage of three targets
is in line with other works for testing screening algorithms.<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref63">63</xref>−<xref ref-type="bibr" rid="ref65">65</xref></sup></p>
      <p>ELIXIR-A refined pharmacophores were extracted
from the overlaid points (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>, right). Five features with three different types
were built from 20 initial features. The HIVPR pharmacophore model
prepared directly by Pharmit could not generate any screened results
because the initial model contained too many pharmacophore features,
confirming the need for a tool to refine pharmacophores for effective
virtual screening. To compare the performance of ELIXIR-A in comparison
to other software capable of pharmacophore screening, we ran the screening
algorithms using ∼25,000 starting molecules for three distinct
receptors.</p>
      <p>For HIVPR, the ELIXIR-A algorithm was able to output
19 molecules,
with three being active (3/536) with an enrichment factor of 10.69
(<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). LigandScout
was able to retrieve ∼47% active compounds (253/536), while
the enrichment factor was only 4.91. Phase found three aromatic ring
features based on the alignment of two structure-based complexes.
The enrichment factor of 0.45 suggested that this model did not match
the true binding modes. HIVPR has four key hydrophobic features located
in the drug pocket, which are important for binding.<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref66">66</xref></sup> ELIXIR-A and LigandScout both found three of the four hydrophobic
features for virtual screening (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). Thus, high enrichment factors were obtained using
ELIXIR-A and LigandScout for the HIVPR target.</p>
      <fig id="fig5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Refined pharmacophore
models of HIVPR generated by ELIXIR-A (A),
LigandScout (B), and Phase (C).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0006" id="gr5" position="float"/>
      </fig>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Enrichment Analysis for Refined Pharmacophore
Models</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center"> </th>
              <th colspan="2" align="center">active
and inactive compounds in the dataset<hr/></th>
              <th colspan="3" align="center">virtual screening results<xref rid="t2fn2" ref-type="table-fn">b</xref><hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">approach</th>
              <th style="border:none;" align="center">target</th>
              <th style="border:none;" align="center">active</th>
              <th style="border:none;" align="center">decoy</th>
              <th style="border:none;" align="center">active</th>
              <th style="border:none;" align="center">decoy</th>
              <th style="border:none;" align="center" char=".">EF</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">ELIXIR-A</td>
              <td rowspan="3" style="border:none;" align="left">HIVPR</td>
              <td rowspan="3" style="border:none;" align="left">536</td>
              <td rowspan="3" style="border:none;" align="left">35,750</td>
              <td style="border:none;" align="left">3</td>
              <td style="border:none;" align="left">16</td>
              <td style="border:none;" align="char" char=".">10.69</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">LigandScout</td>
              <td style="border:none;" align="left">253</td>
              <td style="border:none;" align="left">3236</td>
              <td style="border:none;" align="char" char=".">4.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Phase</td>
              <td style="border:none;" align="left">36</td>
              <td style="border:none;" align="left">5409</td>
              <td style="border:none;" align="char" char=".">0.45</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ELIXIR-A</td>
              <td rowspan="3" style="border:none;" align="left">ACES</td>
              <td rowspan="3" style="border:none;" align="left">408</td>
              <td rowspan="3" style="border:none;" align="left">26,250</td>
              <td style="border:none;" align="left">201</td>
              <td style="border:none;" align="left">3349</td>
              <td style="border:none;" align="char" char=".">3.70</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">LigandScout</td>
              <td style="border:none;" align="left">190</td>
              <td style="border:none;" align="left">2913</td>
              <td style="border:none;" align="char" char=".">4.00</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Phase</td>
              <td style="border:none;" align="left">167</td>
              <td style="border:none;" align="left">8308</td>
              <td style="border:none;" align="char" char=".">1.29</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ELIXIR-A</td>
              <td rowspan="3" style="border:none;" align="left">CDK2</td>
              <td rowspan="3" style="border:none;" align="left">335</td>
              <td rowspan="3" style="border:none;" align="left">27,850</td>
              <td style="border:none;" align="left">189</td>
              <td style="border:none;" align="left">1597</td>
              <td style="border:none;" align="char" char=".">8.90</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">LigandScout<xref rid="t2fn1" ref-type="table-fn">a</xref></td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="char" char="."> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Phase</td>
              <td style="border:none;" align="left">33</td>
              <td style="border:none;" align="left">345</td>
              <td style="border:none;" align="char" char=".">7.34</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p>LigandScout
lacked sufficient independent
matching of pharmacophore features within tolerances to generate alignment.</p>
          </fn>
          <fn id="t2fn2">
            <label>b</label>
            <p>Some molecules in the dataset
have
multiple tautomer confirmations. The output will only include a unique
active/decoy molecule with minimum RMSD from pharmacophore matching.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>For ACES, ELIXIR-A was able
to retrieve ∼50% (201/408) active
compounds with an enrichment factor of 3.70 (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). LigandScout was able to retrieve ∼47%
active molecules with an enrichment factor of 4.00. Phase retrieved
∼40% active molecules with an enrichment factor of 1.29 due
to the high number of screened decoys (8038/26250). The ACES active
binding pocket was long, narrow, and hydrophobic.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Conserved aromatic residues were found at the peripheral
site.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> All three algorithms in this study
modeled one hydrophobic feature at the active site and two hydrophobic
or aromatic features at the peripheral site (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Comparatively, ELIXIR-A was able to match
the highest number of active compounds in the dataset.</p>
      <fig id="fig6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Refined pharmacophore
models of ACES generated by ELIXIR-A (A),
LigandScout (B), and Phase (C).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0007" id="gr6" position="float"/>
      </fig>
      <p>For CDK2, ELIXIR-A was able to retrieve ∼55% (189/335) active
compounds with an enrichment factor of 8.90 (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Phase retrieved ∼10% (33/335) active
molecules with an enrichment factor of 7.34. Multiple CDK2 pharmacophores
were reported with different pharmacophore features.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> Meanwhile, most of them include one hydrogen bond acceptor,
one hydrogen bond donor, and two hydrophobic features. The ELIXIR-A
model included all these common features and therefore matched half
of the active compounds in the dataset (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). The Phase model recognizes the nonpolar
features as the aromatic rings, which matched 10% of the active molecules.
Here, ELIXIR-A was able to retrieve a much higher number of active
compounds as compared to Phase, while LigandScout failed to retrieve
any.</p>
      <fig id="fig7" position="float">
        <label>Figure 7</label>
        <caption>
          <p>Refined pharmacophore models of CDK2 generated by ELIXIR-A (A)
and Phase (B).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_0008" id="gr7" position="float"/>
      </fig>
      <p>This benchmark compound validation
indicated that ELIXIR-A could
be a valuable tool to refine pharmacophores for better enrichment
during virtual screening.</p>
      <p>The physicochemical properties of
ligands screened by various pharmacophore
refinement models were compared (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.1c07144/suppl_file/ao1c07144_si_001.pdf">Table S3</ext-link>). It is noted that at least one of the physicochemical properties
(<italic>M</italic><sub>W</sub>, TPSA, or log<italic>P</italic>) differed
significantly between the active and decoy molecules in the seven
models. In the ACES-ELIXIR-A model, <italic>M</italic><sub>W</sub>, TPSA, and log<italic>P</italic> showed significant differences.
In the CDK2-ELIXIR-A model, <italic>M</italic><sub>W</sub> and log<italic>P</italic> showed a significant difference. These results suggested
that ELIXIR-A was able to satisfactorily differentiate between active
and decoy molecules in terms of key physicochemical aspects. It is
noted that further physicochemical studies such as QSAR could be utilized
to further enhance the ELIXIR-A pharmacophore refinement platform.</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Discussion</title>
    <p>Pharmacophores are a set of steric and electronic
features that
recognize optimal supramolecular interactions. Structure-based modeling
using protein–ligand interactions and ligand-based modeling
using common chemical features from a set of active/inactive ligands
are the two common approaches for building 3D pharmacophore models.<sup><xref ref-type="bibr" rid="ref69">69</xref>,<xref ref-type="bibr" rid="ref70">70</xref></sup> ELIXIR-A is not typical pharmacophore modeling software; rather,
it is a pharmacophore refinement algorithm that uses sets of pharmacophores
as input and aligns these pharmacophores in 3D space to identify any
overlap. ELIXIR-A uses a computer vision-inspired ICP variant algorithm
to align multiple pharmacophore models with similar geometric and
physicochemical properties as point clouds into a refined point cloud.
Although researchers have applied this ICP algorithm for drug discovery
to match three-dimensional protein structures<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> as well as the alignment of protein binding cavities,<sup><xref ref-type="bibr" rid="ref72">72</xref>,<xref ref-type="bibr" rid="ref73">73</xref></sup> it has not been used for pharmacophore refinement. ELIXIR-A fills
this need.</p>
    <p>ELIXIR-A uses a geometry-based approach to find pharmacophore
similarity
between two protein–ligand binding pockets before calculating
the binding energy between the receptor and small ligand molecules
using colored ICP. ICP requires a good initial transformation to ensure
that the point cloud converges to a minimum acceptable value.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> Also, the presence of outliers (nonuniform points)
can affect the alignment in ICP. ELIXIR-A utilizes FPFH matching and
RANSAC iterations to solve the global fitting and outlier problems.
Another algorithm that can perform similar calculations is the Kabsch
algorithm. The Kabsch algorithm is widely used in bioinformatics and
can calculate the RMSD between two 3D protein or pharmacophore structures
via rotation and translation.<sup><xref ref-type="bibr" rid="ref75">75</xref>,<xref ref-type="bibr" rid="ref76">76</xref></sup> When the point correspondences
are known, the Kabsch algorithm can be applied. Since point correspondences
are not known, the Kabsch algorithm cannot be applied here and thus
ICP was used. When using colored ICP, the whole cloud is paired to
figure out the corresponding point, and the points in one group can
be mapped with multiple corresponding points in the other group. It
is also possible to find some important unpaired pharmacophore points
when comparing the output results. Another algorithm that is commonly
used for ligand-based pharmacophore generation is linear assignment
for molecular dataset alignment (LAMDA), which finds globally optimal
pairing between objects.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> LAMDA was not
considered for ELIXIR-A due to its limitation in ligand-based pharmacophore
generation. Genetic algorithms (GA) were used to calculate the initial
transformation position before ICP transformation.<sup><xref ref-type="bibr" rid="ref77">77</xref>−<xref ref-type="bibr" rid="ref80">80</xref></sup> For example, GA is used for pharmacophore
generation via molecular docking-based data sets such as AutoDock
Vina.<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> Meanwhile, ELIXIR-A used FPFH matching
with RANSAC iteration for global alignment. This is mainly because
of the good compatibility between Global Registration and color ICP
supported by Open3D. Although ELIXIR-A currently cannot use GA, when
the molecular structures of the compared proteins are very different,
such a powerful algorithm would be helpful to optimize refinement
results.</p>
    <p>For the initial pharmacophore analysis, ELIXIR-A and
LigandScout
used the same method to find the rigid superposition of two pharmacophore
clusters, while ELIXIR-A used the ICP variant algorithm and LigandScout
used the Hungarian algorithm. In general, the time complexity of the
ICP algorithm in ELIXIR-A was O(N<sup>2</sup>), and the time complexity
of the Hungarian algorithm ranged from O(N<sup>4</sup>) to O(N<sup>3</sup>). Thus, ELIXIR-A provided better time complexity with the
potential to efficiently solve large pharmacophore alignment problems.</p>
  </sec>
  <sec id="sec5">
    <title>Conclusions</title>
    <p>ELIXIR-A is a python-based VMD plugin used to help refine pharmacophore
models in situations where a large number of pharmacophores are present
from multiple models due to various ligand–receptor interactions
and many conformations of a ligand on a receptor binding site. The
ELIXIR-A GUI can help refine the pharmacophores generated from multiple
ligands from multiple receptors using the ICP variant algorithm. The
output from ELIXIR-A can be used in virtual pharmacophore-based platforms
for compound screening.</p>
    <sec id="sec5.1">
      <title>Requirements and Availability</title>
      <p>The
ELIXIR-A package
was developed in python3 for the data operations and tcl/tk for the
user interface. The package was tested on the Ubuntu 20.04, macOS
Big Sur, and Windows 10 systems. The python versions were 3.7.4 or
later. The latest version of ELXIR-A is available for download on
GitHub (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/sfernando-BAEN/ELIXIR-A/releases">https://github.com/sfernando-BAEN/ELIXIR-A/releases</uri>). VMD was
downloaded from their official websites. A 64-bit version of VMD is
recommended for this package. ELIXIR-A follows the Apache-2.0 license
and is open-source on GitHub.</p>
    </sec>
  </sec>
</body>
<back>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.1c07144?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.1c07144</ext-link>.<list id="silist" list-type="simple"><list-item><p>Additional pharmacophore
definitions, a record of the
ELIXIR-A input and output pdb files, selected physicochemical properties
of the pharmacophore models, and pharmacophore output figures (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.1c07144/suppl_file/ao1c07144_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c07144_si_001.pdf">
        <caption>
          <p>ao1c07144_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes1">
    <title>Author Contributions</title>
    <p>H.W. developed
the ELIXIR-A tool, analyzed the data, and wrote the manuscript. N.M.
contributed to the discussion and wrote the manuscript. L.M.P. and
S.F. reviewed the manuscript and supervised the overall research.</p>
  </notes>
  <notes notes-type="COI-statement" id="NOTES-d7e1274-autogenerated">
    <p>The authors declare
no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors gratefully appreciate the support from
the Texas A&amp;M High Performance Research Computing (HPRC) group.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Jana</surname><given-names>S.</given-names></name>; <name><surname>Ganeshpurkar</surname><given-names>A.</given-names></name>; <name><surname>Singh</surname><given-names>S. K.</given-names></name><article-title>Multiple 3D-QSAR modeling, e-pharmacophore,
molecular docking, and in vitro study to explore novel AChE inhibitors</article-title>. <source>RSC Adv.</source><year>2018</year>, <volume>8</volume>, <fpage>39477</fpage>–<lpage>39495</lpage>. <pub-id pub-id-type="doi">10.1039/C8RA08198K</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Lauria</surname><given-names>A.</given-names></name>; <name><surname>Ippolito</surname><given-names>M.</given-names></name>; <name><surname>Fazzari</surname><given-names>M.</given-names></name>; <name><surname>Tutone</surname><given-names>M.</given-names></name>; <name><surname>Di Blasi</surname><given-names>F.</given-names></name>; <name><surname>Mingoia</surname><given-names>F.</given-names></name>; <name><surname>Almerico</surname><given-names>A. M.</given-names></name><article-title>IKK-β
inhibitors: An analysis
of drug–receptor interaction by using Molecular Docking and
Pharmacophore 3D-QSAR approaches</article-title>. <source>J. Mol. Graphics
Modell.</source><year>2010</year>, <volume>29</volume>, <fpage>72</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2010.04.008</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Wan</surname><given-names>Y.</given-names></name>; <name><surname>Ju</surname><given-names>X.</given-names></name>; <name><surname>Gu</surname><given-names>S.</given-names></name><article-title>Application
of 3D-QSAR, pharmacophore, and molecular docking in the molecular
design of diarylpyrimidine derivatives as HIV-1 nonnucleoside reverse
transcriptase inhibitors</article-title>. <source>Int. J. Mol. Sci.</source><year>2018</year>, <volume>19</volume>, <fpage>1436</fpage><pub-id pub-id-type="doi">10.3390/ijms19051436</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Ehrlich</surname><given-names>P.</given-names></name><article-title>Über
den jetzigen Stand der Chemotherapie</article-title>. <source>Ber. Dtsch.
Chem. Ges.</source><year>1909</year>, <volume>42</volume>, <fpage>17</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1002/cber.19090420105</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Wermuth</surname><given-names>C.-G.</given-names></name>; <name><surname>Ganellin</surname><given-names>C. R.</given-names></name>; <name><surname>Lindberg</surname><given-names>P.</given-names></name>; <name><surname>Mitscher</surname><given-names>L. A.</given-names></name><article-title>Glossary of terms
used in medicinal chemistry (IUPAC Recommendations 1997)</article-title>. <source>Annu. Rep. Med. Chem.</source><year>1998</year>, <volume>33</volume>, <fpage>385</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-7743(08)61101-X</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="book" id="cit6"><person-group person-group-type="allauthors"><name><surname>Gund</surname><given-names>P.</given-names></name></person-group><article-title>Three-dimensional
pharmacophoric pattern searching</article-title>. In <source>Progress
in molecular and subcellular biology</source>; <publisher-name>Springer</publisher-name>, <year>1977</year>; pp. <fpage>117</fpage>–<lpage>143</lpage>.</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Yang</surname><given-names>S.-Y.</given-names></name><article-title>Pharmacophore
modeling and applications in drug discovery: challenges and recent
advances</article-title>. <source>Drug Discovery Today</source><year>2010</year>, <volume>15</volume>, <fpage>444</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2010.03.013</pub-id>.<pub-id pub-id-type="pmid">20362693</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Wolber</surname><given-names>G.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name><article-title>LigandScout: 3-D pharmacophores derived
from protein-bound
ligands and their use as virtual screening filters</article-title>. <source>J. Chem. Inf. Model.</source><year>2005</year>, <volume>45</volume>, <fpage>160</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1021/ci049885e</pub-id>.<pub-id pub-id-type="pmid">15667141</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="book" id="cit9"><person-group person-group-type="allauthors"><name><surname>Martin</surname><given-names>Y. C.</given-names></name></person-group><article-title>DISCO: what
we did right and what we missed</article-title>. <source>Pharmacophore
perception, development, and use in drug design</source><italic>;</italic><publisher-name>International University Line</publisher-name><year>2000</year><bold>,</bold><volume>2</volume>, <fpage>49</fpage>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="book" id="cit10"><person-group person-group-type="allauthors"><name><surname>Jones</surname><given-names>G.</given-names></name>; <name><surname>Willet</surname><given-names>P.</given-names></name>; <name><surname>Glen</surname><given-names>R.</given-names></name></person-group><article-title>GASP: genetic algorithm superimposition
program</article-title>. <source>Pharmacophore perception, development,
and use in drug design</source><italic>;</italic><publisher-name>International University Line</publisher-name><year>2000</year>, <fpage>85</fpage>–<lpage>106</lpage>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="weblink" id="cit11"><source>GALAHAD<sup>TM</sup></source> is distributed by <publisher-name>Tripos
Inc.</publisher-name>, <person-group person-group-type="allauthors"><name><surname>St. Louis</surname><given-names>S. H. R.</given-names></name></person-group>, , MO 63144, USA (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.tripos.com">http://www.tripos.com</uri>).</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Barnum</surname><given-names>D.</given-names></name>; <name><surname>Greene</surname><given-names>J.</given-names></name>; <name><surname>Smellie</surname><given-names>A.</given-names></name>; <name><surname>Sprague</surname><given-names>P.</given-names></name><article-title>Identification
of common
functional configurations among molecules</article-title>. <source>J.
Chem. Inf. Comput. Sci.</source><year>1996</year>, <volume>36</volume>, <fpage>563</fpage>–<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1021/ci950273r</pub-id>.<pub-id pub-id-type="pmid">8690757</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="book" id="cit13"><person-group person-group-type="allauthors"><name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Sutter</surname><given-names>J.</given-names></name>; <name><surname>Hoffmann</surname><given-names>R.</given-names></name></person-group><article-title>HypoGen:
an automated
system for generating 3D predictive pharmacophore models</article-title>. <source>Pharmacophore perception, development, and use in drug
design</source><italic>;</italic><publisher-name>International University
Line</publisher-name><year>2000</year><bold>,</bold><volume>2</volume>, <fpage>171</fpage>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name>; <name><surname>Dror</surname><given-names>O.</given-names></name>; <name><surname>Inbar</surname><given-names>Y.</given-names></name>; <name><surname>Nussinov</surname><given-names>R.</given-names></name>; <name><surname>Wolfson</surname><given-names>H. J.</given-names></name><article-title>PharmaGist:
a webserver for ligand-based pharmacophore detection</article-title>. <source>Nucleic Acids Res.</source><year>2008</year>, <volume>36</volume>, <fpage>W223</fpage>–<lpage>W228</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn187</pub-id>.<pub-id pub-id-type="pmid">18424800</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Brown</surname><given-names>B. P.</given-names></name>; <name><surname>Mendenhall</surname><given-names>J.</given-names></name>; <name><surname>Meiler</surname><given-names>J.</given-names></name><article-title>BCL:: MolAlign: Three-Dimensional
Small Molecule Alignment for Pharmacophore Mapping</article-title>. <source>J. Chem. Inf. Model.</source><year>2019</year>, <volume>59</volume>, <fpage>689</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00020</pub-id>.<pub-id pub-id-type="pmid">30707580</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Dixon</surname><given-names>S. L.</given-names></name>; <name><surname>Smondyrev</surname><given-names>A. M.</given-names></name>; <name><surname>Knoll</surname><given-names>E. H.</given-names></name>; <name><surname>Rao</surname><given-names>S. N.</given-names></name>; <name><surname>Shaw</surname><given-names>D. E.</given-names></name>; <name><surname>Friesner</surname><given-names>R. A.</given-names></name><article-title>PHASE:
a new engine for pharmacophore perception, 3D
QSAR model development, and 3D database screening: 1. Methodology
and preliminary results</article-title>. <source>J. Comput.-Aided Mol.
Des.</source><year>2006</year>, <volume>20</volume>, <fpage>647</fpage>–<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-006-9087-6</pub-id>.<pub-id pub-id-type="pmid">17124629</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Ortuso</surname><given-names>F.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name>; <name><surname>Alcaro</surname><given-names>S.</given-names></name><article-title>GBPM: GRID-based
pharmacophore model:
concept and application studies to protein–protein recognition</article-title>. <source>Bioinformatics</source><year>2006</year>, <volume>22</volume>, <fpage>1449</fpage>–<lpage>1455</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btl115</pub-id>.<pub-id pub-id-type="pmid">16567363</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Sunseri</surname><given-names>J.</given-names></name>; <name><surname>Koes</surname><given-names>D. R.</given-names></name><article-title>Pharmit: interactive exploration of chemical space</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>, <volume>44</volume>, <fpage>W442</fpage>–<lpage>W448</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw287</pub-id>.<pub-id pub-id-type="pmid">27095195</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Lai</surname><given-names>L.</given-names></name><article-title>Pocket v. 2: further
developments on receptor-based pharmacophore
modeling</article-title>. <source>J. Chem. Inf. Model.</source><year>2006</year>, <volume>46</volume>, <fpage>2684</fpage>–<lpage>2691</lpage>. <pub-id pub-id-type="doi">10.1021/ci600246s</pub-id>.<pub-id pub-id-type="pmid">17125208</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>; <name><surname>Pei</surname><given-names>J.</given-names></name>; <name><surname>Lai</surname><given-names>L.</given-names></name><article-title>Protein-protein interface
analysis and hot spots identification for chemical ligand design</article-title>. <source>Curr. Pharm. Des.</source><year>2014</year>, <volume>20</volume>, <fpage>1192</fpage>–<lpage>1200</lpage>. <pub-id pub-id-type="doi">10.2174/13816128113199990065</pub-id>.<pub-id pub-id-type="pmid">23713772</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Schaller</surname><given-names>D.</given-names></name>; <name><surname>Pach</surname><given-names>S.</given-names></name>; <name><surname>Wolber</surname><given-names>G.</given-names></name><article-title>PyRod: Tracing water molecules in
molecular dynamics simulations</article-title>. <source>J. Chem. Inf.
Model.</source><year>2019</year>, <volume>59</volume>, <fpage>2818</fpage>–<lpage>2829</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00281</pub-id>.<pub-id pub-id-type="pmid">31117512</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Koes</surname><given-names>D. R.</given-names></name>; <name><surname>Camacho</surname><given-names>C. J.</given-names></name><article-title>ZINCPharmer: pharmacophore
search of the ZINC database</article-title>. <source>Nucleic Acids Res.</source><year>2012</year>, <volume>40</volume>, <fpage>W409</fpage>–<lpage>W414</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks378</pub-id>.<pub-id pub-id-type="pmid">22553363</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Schaller</surname><given-names>D.</given-names></name>; <name><surname>Šribar</surname><given-names>D.</given-names></name>; <name><surname>Noonan</surname><given-names>T.</given-names></name>; <name><surname>Deng</surname><given-names>L.</given-names></name>; <name><surname>Nguyen</surname><given-names>T. N.</given-names></name>; <name><surname>Pach</surname><given-names>S.</given-names></name>; <name><surname>Machalz</surname><given-names>D.</given-names></name>; <name><surname>Bermudez</surname><given-names>M.</given-names></name>; <name><surname>Wolber</surname><given-names>G.</given-names></name><article-title>Next generation
3D pharmacophore modeling</article-title>. <source>Wiley Interdiscip.
Rev.: Comput. Mol. Sci.</source><year>2020</year>, <volume>10</volume>, <elocation-id>e1468</elocation-id><pub-id pub-id-type="doi">10.1002/wcms.1468</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>McGregor</surname><given-names>M. J.</given-names></name>; <name><surname>Muskal</surname><given-names>S. M.</given-names></name><article-title>Pharmacophore fingerprinting.
1. Application to QSAR
and focused library design</article-title>. <source>J. Chem. Inf. Comput.
Sci.</source><year>1999</year>, <volume>39</volume>, <fpage>569</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1021/ci980159j</pub-id>.<pub-id pub-id-type="pmid">10361729</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Bonachéra</surname><given-names>F.</given-names></name>; <name><surname>Parent</surname><given-names>B.</given-names></name>; <name><surname>Barbosa</surname><given-names>F.</given-names></name>; <name><surname>Froloff</surname><given-names>N.</given-names></name>; <name><surname>Horvath</surname><given-names>D.</given-names></name><article-title>Fuzzy tricentric
pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets
and adapted molecular similarity scoring schemes</article-title>. <source>J. Chem. Inf. Model.</source><year>2006</year>, <volume>46</volume>, <fpage>2457</fpage>–<lpage>2477</lpage>. <pub-id pub-id-type="doi">10.1021/ci6002416</pub-id>.<pub-id pub-id-type="pmid">17125187</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Wood</surname><given-names>D. J.</given-names></name>; <name><surname>Vlieg</surname><given-names>J. d.</given-names></name>; <name><surname>Wagener</surname><given-names>M.</given-names></name>; <name><surname>Ritschel</surname><given-names>T.</given-names></name><article-title>Pharmacophore fingerprint-based
approach to binding site subpocket similarity and its application
to bioisostere replacement</article-title>. <source>J. Chem. Inf. Model.</source><year>2012</year>, <volume>52</volume>, <fpage>2031</fpage>–<lpage>2043</lpage>. <pub-id pub-id-type="doi">10.1021/ci3000776</pub-id>.<pub-id pub-id-type="pmid">22830492</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Warszycki</surname><given-names>D.</given-names></name>; <name><surname>Struski</surname><given-names>Ł.</given-names></name>; <name><surname>Śmieja</surname><given-names>M.</given-names></name>; <name><surname>Kafel</surname><given-names>R.</given-names></name>; <name><surname>Kurczab</surname><given-names>R.</given-names></name><article-title>Pharmacoprint:
A Combination of a Pharmacophore Fingerprint and Artificial Intelligence
as a Tool for Computer-Aided Drug Design</article-title>. <source>J.
Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume>, <fpage>5054</fpage>–<lpage>5065</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00589</pub-id>.<pub-id pub-id-type="pmid">34547888</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Vásquez-Dománguez</surname><given-names>E.</given-names></name>; <name><surname>Armijos-Jaramillo</surname><given-names>V. D.</given-names></name>; <name><surname>Tejera</surname><given-names>E.</given-names></name>; <name><surname>González-Dáaz</surname><given-names>H.</given-names></name><article-title>Multioutput
perturbation-theory machine learning (PTML) model of ChEMBL data for
antiretroviral compounds</article-title>. <source>Mol. Pharmaceutics</source><year>2019</year>, <volume>16</volume>, <fpage>4200</fpage>–<lpage>4212</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00538</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Kleandrova</surname><given-names>V. V.</given-names></name>; <name><surname>Scotti</surname><given-names>M. T.</given-names></name>; <name><surname>Scotti</surname><given-names>L.</given-names></name>; <name><surname>Speck-Planche</surname><given-names>A.</given-names></name><article-title>Multi-target
drug discovery via ptml modeling: applications to the design of virtual
dual inhibitors of cdk4 and her2</article-title>. <source>Curr. Top.
Med. Chem.</source><year>2021</year>, <volume>21</volume>, <fpage>661</fpage>–<lpage>675</lpage>. <pub-id pub-id-type="doi">10.2174/1568026621666210119112845</pub-id>.<pub-id pub-id-type="pmid">33463472</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Sato</surname><given-names>T.</given-names></name>; <name><surname>Honma</surname><given-names>T.</given-names></name>; <name><surname>Yokoyama</surname><given-names>S.</given-names></name><article-title>Combining
machine learning and pharmacophore-based
interaction fingerprint for in silico screening</article-title>. <source>J. Chem. Inf. Model.</source><year>2010</year>, <volume>50</volume>, <fpage>170</fpage>–<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1021/ci900382e</pub-id>.<pub-id pub-id-type="pmid">20038188</pub-id></mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Hu</surname><given-names>Q.</given-names></name>; <name><surname>Gao</surname><given-names>S.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Shen</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>F.</given-names></name>; <name><surname>Lai</surname><given-names>L.</given-names></name>; <name><surname>Pei</surname><given-names>J.</given-names></name><article-title>CavityPlus: a web server for protein cavity detection
with pharmacophore
modelling, allosteric site identification and covalent ligand binding
ability prediction</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume>, <fpage>W374</fpage>–<lpage>W379</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky380</pub-id>.<pub-id pub-id-type="pmid">29750256</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Goodford</surname><given-names>P. J.</given-names></name><article-title>A computational
procedure for determining energetically favorable binding sites on
biologically important macromolecules</article-title>. <source>J. Med.
Chem.</source><year>1985</year>, <volume>28</volume>, <fpage>849</fpage>–<lpage>857</lpage>. <pub-id pub-id-type="doi">10.1021/jm00145a002</pub-id>.<pub-id pub-id-type="pmid">3892003</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Barillari</surname><given-names>C.</given-names></name>; <name><surname>Marcou</surname><given-names>G.</given-names></name>; <name><surname>Rognan</surname><given-names>D.</given-names></name><article-title>Hot-spots-guided
receptor-based pharmacophores
(HS-Pharm): a knowledge-based approach to identify ligand-anchoring
atoms in protein cavities and prioritize structure-based pharmacophores</article-title>. <source>J. Chem. Inf. Model.</source><year>2008</year>, <volume>48</volume>, <fpage>1396</fpage>–<lpage>1410</lpage>. <pub-id pub-id-type="doi">10.1021/ci800064z</pub-id>.<pub-id pub-id-type="pmid">18570371</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Tran-Nguyen</surname><given-names>V.-K.</given-names></name>; <name><surname>Da Silva</surname><given-names>F.</given-names></name>; <name><surname>Bret</surname><given-names>G.</given-names></name>; <name><surname>Rognan</surname><given-names>D.</given-names></name><article-title>All in one: Cavity
detection, druggability estimate, cavity-based pharmacophore perception,
and virtual screening</article-title>. <source>J. Chem. Inf. Model.</source><year>2019</year>, <volume>59</volume>, <fpage>573</fpage>–<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00684</pub-id>.<pub-id pub-id-type="pmid">30563339</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Schuetz</surname><given-names>D. A.</given-names></name>; <name><surname>Seidel</surname><given-names>T.</given-names></name>; <name><surname>Garon</surname><given-names>A.</given-names></name>; <name><surname>Martini</surname><given-names>R.</given-names></name>; <name><surname>Körbel</surname><given-names>M.</given-names></name>; <name><surname>Ecker</surname><given-names>G. F.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name><article-title>GRAIL: Grids of pharmacophore
interaction
fields</article-title>. <source>J. Chem. Theory Comput.</source><year>2018</year>, <volume>14</volume>, <fpage>4958</fpage>–<lpage>4970</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.8b00495</pub-id>.<pub-id pub-id-type="pmid">30075621</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Verdonk</surname><given-names>M. L.</given-names></name>; <name><surname>Cole</surname><given-names>J. C.</given-names></name>; <name><surname>Taylor</surname><given-names>R.</given-names></name><article-title>SuperStar: a knowledge-based
approach
for identifying interaction sites in proteins</article-title>. <source>J. Mol. Biol.</source><year>1999</year>, <volume>289</volume>, <fpage>1093</fpage>–<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1999.2809</pub-id>.<pub-id pub-id-type="pmid">10369784</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Yu</surname><given-names>W.</given-names></name>; <name><surname>Lakkaraju</surname><given-names>S. K.</given-names></name>; <name><surname>Raman</surname><given-names>E. P.</given-names></name>; <name><surname>Fang</surname><given-names>L.</given-names></name>; <name><surname>MacKerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name><article-title>Pharmacophore modeling using site-identification by
ligand competitive saturation (SILCS) with multiple probe molecules</article-title>. <source>J. Chem. Inf. Model.</source><year>2015</year>, <volume>55</volume>, <fpage>407</fpage>–<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1021/ci500691p</pub-id>.<pub-id pub-id-type="pmid">25622696</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Yu</surname><given-names>W.</given-names></name>; <name><surname>Lakkaraju</surname><given-names>S. K.</given-names></name>; <name><surname>Raman</surname><given-names>E. P.</given-names></name>; <name><surname>MacKerell</surname><given-names>A. D.</given-names><suffix>Jr.</suffix></name><article-title>Site-identification
by ligand competitive saturation
(SILCS) assisted pharmacophore modeling</article-title>. <source>J.
Comput.-Aided Mol. Des.</source><year>2014</year>, <volume>28</volume>, <fpage>491</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-014-9728-0</pub-id>.<pub-id pub-id-type="pmid">24610239</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name><surname>Krieger</surname><given-names>J. M.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Bahar</surname><given-names>I.</given-names></name><article-title>Pharmmaker: Pharmacophore
modeling and hit identification based on druggability simulations</article-title>. <source>Protein Sci.</source><year>2020</year>, <volume>29</volume>, <fpage>76</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3732</pub-id>.<pub-id pub-id-type="pmid">31576621</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Bakan</surname><given-names>A.</given-names></name>; <name><surname>Nevins</surname><given-names>N.</given-names></name>; <name><surname>Lakdawala</surname><given-names>A. S.</given-names></name>; <name><surname>Bahar</surname><given-names>I.</given-names></name><article-title>Druggability assessment
of allosteric proteins by dynamics simulations in the presence of
probe molecules</article-title>. <source>J. Chem. Theory Comput.</source><year>2012</year>, <volume>8</volume>, <fpage>2435</fpage>–<lpage>2447</lpage>. <pub-id pub-id-type="doi">10.1021/ct300117j</pub-id>.<pub-id pub-id-type="pmid">22798729</pub-id></mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Humphrey</surname><given-names>W.</given-names></name>; <name><surname>Dalke</surname><given-names>A.</given-names></name>; <name><surname>Schulten</surname><given-names>K.</given-names></name><article-title>VMD: visual molecular dynamics</article-title>. <source>J. Mol. Graph.</source><year>1996</year>, <volume>14</volume>, <fpage>33</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id>.<pub-id pub-id-type="pmid">8744570</pub-id></mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="undeclared" id="cit42"><person-group person-group-type="allauthors"><name><surname>Zhou</surname><given-names>Q.-Y.</given-names></name>; <name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Koltun</surname><given-names>V.</given-names></name></person-group><article-title>Open3D: A modern
library for 3D data processing</article-title>. <source>arXiv preprint
arXiv:1801.09847</source><year>2018</year>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="book" id="cit43"><person-group person-group-type="allauthors"><name><surname>Zhou</surname><given-names>Q.-Y.</given-names></name>; <name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Koltun</surname><given-names>V.</given-names></name></person-group> In <article-title>Fast global
registration</article-title>. <source>European conference on computer
vision</source>; <publisher-name>Springer</publisher-name>, <year>2016</year>; pp. <fpage>766</fpage>–<lpage>782</lpage>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="book" id="cit44"><person-group person-group-type="allauthors"><name><surname>Park</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>Q.-Y.</given-names></name>; <name><surname>Koltun</surname><given-names>V.</given-names></name></person-group> In <article-title>Colored point cloud registration
revisited</article-title><italic>.</italic><source>Proceedings of
the IEEE international conference on computer vision</source>; <publisher-name>ICCV</publisher-name><year>2017</year>; pp. <fpage>143</fpage>–<lpage>152</lpage>.</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="book" id="cit45"><person-group person-group-type="allauthors"><name><surname>Besl</surname><given-names>P. J.</given-names></name>; <name><surname>McKay</surname><given-names>N. D.</given-names></name></person-group> In <article-title>Method for
registration of 3-D shapes</article-title><italic>.</italic><source>Sensor fusion IV: control paradigms and data structures</source>; <publisher-name>International Society for Optics and Photonics</publisher-name>: <year>1992</year>; pp. <fpage>586</fpage>–<lpage>606</lpage>.</mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="journal" id="cit46"><name><surname>Raschka</surname><given-names>S.</given-names></name><article-title>BioPandas:
Working with molecular structures in pandas DataFrames</article-title>. <source>J. Open Source Softw.</source><year>2017</year>, <volume>2</volume>, <fpage>279</fpage><pub-id pub-id-type="doi">10.21105/joss.00279</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><name><surname>Rusu</surname><given-names>R. B.</given-names></name>; <name><surname>Blodow</surname><given-names>N.</given-names></name>; <name><surname>Beetz</surname><given-names>M.</given-names></name></person-group> In <article-title>Fast point feature histograms
(FPFH) for 3D registration</article-title>. <source>2009 IEEE international
conference on robotics and automation</source>; <publisher-name>IEEE</publisher-name>: <year>2009</year>; pp. <fpage>3212</fpage>–<lpage>3217</lpage>.</mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Fischler</surname><given-names>M. A.</given-names></name>; <name><surname>Bolles</surname><given-names>R. C.</given-names></name><article-title>Random sample consensus:
a paradigm for model fitting
with applications to image analysis and automated cartography</article-title>. <source>Commun. ACM</source><year>1981</year>, <volume>24</volume>, <fpage>381</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1145/358669.358692</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Mysinger</surname><given-names>M. M.</given-names></name>; <name><surname>Carchia</surname><given-names>M.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Directory of useful
decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking</article-title>. <source>J. Med. Chem.</source><year>2012</year>, <volume>55</volume>, <fpage>6582</fpage>–<lpage>6594</lpage>. <pub-id pub-id-type="doi">10.1021/jm300687e</pub-id>.<pub-id pub-id-type="pmid">22716043</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <mixed-citation publication-type="journal" id="cit50"><name><surname>O’Boyle</surname><given-names>N. M.</given-names></name>; <name><surname>Banck</surname><given-names>M.</given-names></name>; <name><surname>James</surname><given-names>C. A.</given-names></name>; <name><surname>Morley</surname><given-names>C.</given-names></name>; <name><surname>Vandermeersch</surname><given-names>T.</given-names></name>; <name><surname>Hutchison</surname><given-names>G. R.</given-names></name><article-title>Open Babel: An open chemical toolbox</article-title>. <source>Aust. J. Chem.</source><year>2011</year>, <volume>3</volume>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref51">
      <mixed-citation publication-type="journal" id="cit51"><name><surname>Sealy
Gossetm</surname><given-names>W. S.</given-names></name><article-title>The probable error of a mean</article-title>. <source>Biometrika</source><year>1908</year>, <fpage>1</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2307/2331554</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref52">
      <mixed-citation publication-type="book" id="cit52"><person-group person-group-type="allauthors"><name><surname>Snedecor</surname><given-names>G. W.</given-names></name></person-group><source>Statistical methods:
applied to experiments in agriculture and biology</source>; <publisher-name>The Iowa state college press</publisher-name>: <year>1956</year>.</mixed-citation>
    </ref>
    <ref id="ref53">
      <mixed-citation publication-type="journal" id="cit53"><name><surname>Hunter</surname><given-names>J. D.</given-names></name><article-title>Matplotlib:
A 2D graphics environment</article-title>. <source>Comput. Sci. Eng.</source><year>2007</year>, <volume>9</volume>, <fpage>90</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref54">
      <mixed-citation publication-type="journal" id="cit54"><name><surname>Van
Der Walt</surname><given-names>S.</given-names></name>; <name><surname>Colbert</surname><given-names>S. C.</given-names></name>; <name><surname>Varoquaux</surname><given-names>G.</given-names></name><article-title>The NumPy
array: a structure for efficient numerical computation</article-title>. <source>Comput. Sci. Eng.</source><year>2011</year>, <volume>13</volume>, <fpage>22</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1109/MCSE.2011.37</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref55">
      <mixed-citation publication-type="book" id="cit55"><person-group person-group-type="allauthors"><name><surname>Schrödinger</surname><given-names>L.</given-names></name></person-group><source>Schrödinger,
Release 2020–4: Maestro</source>; <publisher-name>Schrödinger</publisher-name>: <publisher-loc>LLC</publisher-loc><year>2020</year>.</mixed-citation>
    </ref>
    <ref id="ref56">
      <mixed-citation publication-type="book" id="cit56"><person-group person-group-type="allauthors"><name><surname>Release</surname><given-names>S.</given-names></name></person-group><source>4: Glide</source>; <publisher-name>Schrödinger</publisher-name>: <publisher-loc>LLC, New York,
NY</publisher-loc><year>2018</year>.</mixed-citation>
    </ref>
    <ref id="ref57">
      <mixed-citation publication-type="journal" id="cit57"><name><surname>Yeung</surname><given-names>C. M.</given-names></name>; <name><surname>Klein</surname><given-names>L. L.</given-names></name>; <name><surname>Flentge</surname><given-names>C. A.</given-names></name>; <name><surname>Randolph</surname><given-names>J. T.</given-names></name>; <name><surname>Zhao</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>M.</given-names></name>; <name><surname>Dekhtyar</surname><given-names>T.</given-names></name>; <name><surname>Stoll</surname><given-names>V. S.</given-names></name>; <name><surname>Kempf</surname><given-names>D. J.</given-names></name><article-title>Oximinoarylsulfonamides
as potent HIV protease inhibitors</article-title>. <source>Bioorg. Med.
Chem. Lett.</source><year>2005</year>, <volume>15</volume>, <fpage>2275</fpage>–<lpage>2278</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.03.008</pub-id>.<pub-id pub-id-type="pmid">15837308</pub-id></mixed-citation>
    </ref>
    <ref id="ref58">
      <mixed-citation publication-type="journal" id="cit58"><name><surname>Miller</surname><given-names>J. F.</given-names></name>; <name><surname>Andrews</surname><given-names>C. W.</given-names></name>; <name><surname>Brieger</surname><given-names>M.</given-names></name>; <name><surname>Furfine</surname><given-names>E. S.</given-names></name>; <name><surname>Hale</surname><given-names>M. R.</given-names></name>; <name><surname>Hanlon</surname><given-names>M. H.</given-names></name>; <name><surname>Hazen</surname><given-names>R. J.</given-names></name>; <name><surname>Kaldor</surname><given-names>I.</given-names></name>; <name><surname>McLean</surname><given-names>E. W.</given-names></name>; <name><surname>Reynolds</surname><given-names>D.</given-names></name>; <name><surname>Sammond</surname><given-names>D. M.</given-names></name>; <name><surname>Spaltenstein</surname><given-names>A.</given-names></name>; <name><surname>Tung</surname><given-names>R.</given-names></name>; <name><surname>Turner</surname><given-names>E. M.</given-names></name>; <name><surname>Xu</surname><given-names>R. X.</given-names></name>; <name><surname>Sherrill</surname><given-names>R. G.</given-names></name><article-title>Ultra-potent
P1 modified arylsulfonamide HIV protease inhibitors: the discovery
of GW0385</article-title>. <source>Bioorg. Med. Chem. Lett.</source><year>2006</year>, <volume>16</volume>, <fpage>1788</fpage>–<lpage>1794</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2006.01.035</pub-id>.<pub-id pub-id-type="pmid">16458505</pub-id></mixed-citation>
    </ref>
    <ref id="ref59">
      <mixed-citation publication-type="journal" id="cit59"><name><surname>Bourne</surname><given-names>Y.</given-names></name>; <name><surname>Kolb</surname><given-names>H. C.</given-names></name>; <name><surname>Radić</surname><given-names>Z.</given-names></name>; <name><surname>Sharpless</surname><given-names>K. B.</given-names></name>; <name><surname>Taylor</surname><given-names>P.</given-names></name>; <name><surname>Marchot</surname><given-names>P.</given-names></name><article-title>Freeze-frame inhibitor
captures acetylcholinesterase
in a unique conformation</article-title>. <source>Proc. Natl. Acad.
Sci.</source><year>2004</year>, <volume>101</volume>, <fpage>1449</fpage>–<lpage>1454</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0308206100</pub-id>.<pub-id pub-id-type="pmid">14757816</pub-id></mixed-citation>
    </ref>
    <ref id="ref60">
      <mixed-citation publication-type="journal" id="cit60"><name><surname>Colletier</surname><given-names>J. P.</given-names></name>; <name><surname>Sanson</surname><given-names>B.</given-names></name>; <name><surname>Nachon</surname><given-names>F.</given-names></name>; <name><surname>Gabellieri</surname><given-names>E.</given-names></name>; <name><surname>Fattorusso</surname><given-names>C.</given-names></name>; <name><surname>Campiani</surname><given-names>G.</given-names></name>; <name><surname>Weik</surname><given-names>M.</given-names></name><article-title>Conformational
Flexibility
in the Peripheral Site of Torpedo californica Acetylcholinesterase
Revealed by the Complex Structure with a Bifunctional Inhibitor</article-title>. <source>J. Am. Chem. Soc.</source><year>2006</year>, <volume>128</volume>, <fpage>4526</fpage>–<lpage>4527</lpage>. <pub-id pub-id-type="doi">10.1021/ja058683b</pub-id>.<pub-id pub-id-type="pmid">16594661</pub-id></mixed-citation>
    </ref>
    <ref id="ref61">
      <mixed-citation publication-type="journal" id="cit61"><name><surname>Talapati</surname><given-names>S.
R.</given-names></name>; <name><surname>Nataraj</surname><given-names>V.</given-names></name>; <name><surname>Pothuganti</surname><given-names>M.</given-names></name>; <name><surname>Gore</surname><given-names>S.</given-names></name>; <name><surname>Ramachandra</surname><given-names>M.</given-names></name>; <name><surname>Antony</surname><given-names>T.</given-names></name>; <name><surname>More</surname><given-names>S. S.</given-names></name>; <name><surname>Krishnamurthy</surname><given-names>N. R.</given-names></name><article-title>Structure
of cyclin-dependent kinase 2 (CDK2) in complex with the specific and
potent inhibitor CVT-313</article-title>. <source>Acta Crystallogr.,
Sect. F: Struct. Biol. Commun.</source><year>2020</year>, <volume>76</volume>, <fpage>350</fpage>–<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1107/S2053230X20009243</pub-id>.<pub-id pub-id-type="pmid">32744246</pub-id></mixed-citation>
    </ref>
    <ref id="ref62">
      <mixed-citation publication-type="journal" id="cit62"><name><surname>Echalier</surname><given-names>A.</given-names></name>; <name><surname>Cot</surname><given-names>E.</given-names></name>; <name><surname>Camasses</surname><given-names>A.</given-names></name>; <name><surname>Hodimont</surname><given-names>E.</given-names></name>; <name><surname>Hoh</surname><given-names>F.</given-names></name>; <name><surname>Jay</surname><given-names>P.</given-names></name>; <name><surname>Sheinerman</surname><given-names>F.</given-names></name>; <name><surname>Krasinska</surname><given-names>L.</given-names></name>; <name><surname>Fisher</surname><given-names>D.</given-names></name><article-title>An integrated chemical
biology approach provides insight into Cdk2 functional redundancy
and inhibitor sensitivity</article-title>. <source>Chem. Biol.</source><year>2012</year>, <volume>19</volume>, <fpage>1028</fpage>–<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2012.06.015</pub-id>.<pub-id pub-id-type="pmid">22921070</pub-id></mixed-citation>
    </ref>
    <ref id="ref63">
      <mixed-citation publication-type="journal" id="cit63"><name><surname>Sanders</surname><given-names>M. P. A.</given-names></name>; <name><surname>Barbosa</surname><given-names>A. J. M.</given-names></name>; <name><surname>Zarzycka</surname><given-names>B.</given-names></name>; <name><surname>Nicolaes</surname><given-names>G. A. F.</given-names></name>; <name><surname>Klomp</surname><given-names>J. P. G.</given-names></name>; <name><surname>de Vlieg</surname><given-names>J.</given-names></name>; <name><surname>del Rio</surname><given-names>A.</given-names></name><article-title>Comparative
analysis
of pharmacophore screening tools</article-title>. <source>J. Chem. Inf.
Model.</source><year>2012</year>, <volume>52</volume>, <fpage>1607</fpage>–<lpage>1620</lpage>. <pub-id pub-id-type="doi">10.1021/ci2005274</pub-id>.<pub-id pub-id-type="pmid">22646988</pub-id></mixed-citation>
    </ref>
    <ref id="ref64">
      <mixed-citation publication-type="journal" id="cit64"><name><surname>Spitzer</surname><given-names>G. M.</given-names></name>; <name><surname>Heiss</surname><given-names>M.</given-names></name>; <name><surname>Mangold</surname><given-names>M.</given-names></name>; <name><surname>Markt</surname><given-names>P.</given-names></name>; <name><surname>Kirchmair</surname><given-names>J.</given-names></name>; <name><surname>Wolber</surname><given-names>G.</given-names></name>; <name><surname>Liedl</surname><given-names>K. R.</given-names></name><article-title>One concept,
three implementations
of 3D pharmacophore-based virtual screening: distinct coverage of
chemical search space</article-title>. <source>J. Chem. Inf. Model.</source><year>2010</year>, <volume>50</volume>, <fpage>1241</fpage>–<lpage>1247</lpage>. <pub-id pub-id-type="doi">10.1021/ci100136b</pub-id>.<pub-id pub-id-type="pmid">20583761</pub-id></mixed-citation>
    </ref>
    <ref id="ref65">
      <mixed-citation publication-type="journal" id="cit65"><name><surname>Schuster</surname><given-names>D.</given-names></name><article-title>3D pharmacophores
as tools for activity profiling</article-title>. <source>Drug Discovery
Today: Technol.</source><year>2010</year>, <volume>7</volume>, <fpage>e205</fpage>–<lpage>e211</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2010.11.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref66">
      <mixed-citation publication-type="journal" id="cit66"><name><surname>Lam</surname><given-names>P.</given-names></name>; <name><surname>Jadhav</surname><given-names>P. K.</given-names></name>; <name><surname>Eyermann</surname><given-names>C. J.</given-names></name>; <name><surname>Hodge</surname><given-names>C. N.</given-names></name>; <name><surname>Ru</surname><given-names>Y.</given-names></name>; <name><surname>Bacheler</surname><given-names>L. T.</given-names></name>; <name><surname>Meek</surname><given-names>J. L.</given-names></name>; <name><surname>Otto</surname><given-names>M. J.</given-names></name>; <name><surname>Rayner</surname><given-names>M. M.</given-names></name>; <name><surname>Wong</surname><given-names>Y. N.</given-names></name>; <name><surname>Chang</surname><given-names>C. H.</given-names></name>; <name><surname>Weber</surname><given-names>P. C.</given-names></name>; <name><surname>Jackson</surname><given-names>D. A.</given-names></name>; <name><surname>Sharpe</surname><given-names>T. R.</given-names></name>; <name><surname>Erickson-Viitanen</surname><given-names>S.</given-names></name><article-title>Rational design
of potent, bioavailable,
nonpeptide cyclic ureas as HIV protease inhibitors</article-title>. <source>Science</source><year>1994</year>, <volume>263</volume>, <fpage>380</fpage>–<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1126/science.8278812</pub-id>.<pub-id pub-id-type="pmid">8278812</pub-id></mixed-citation>
    </ref>
    <ref id="ref67">
      <mixed-citation publication-type="journal" id="cit67"><name><surname>Lu</surname><given-names>S.-H.</given-names></name>; <name><surname>Wu</surname><given-names>J. W.</given-names></name>; <name><surname>Liu</surname><given-names>H.-L.</given-names></name>; <name><surname>Zhao</surname><given-names>J.-H.</given-names></name>; <name><surname>Liu</surname><given-names>K.-T.</given-names></name>; <name><surname>Chuang</surname><given-names>C.-K.</given-names></name>; <name><surname>Lin</surname><given-names>H.-Y.</given-names></name>; <name><surname>Tsai</surname><given-names>W.-B.</given-names></name>; <name><surname>Ho</surname><given-names>Y.</given-names></name><article-title>The discovery
of potential acetylcholinesterase inhibitors: a combination of pharmacophore
modeling, virtual screening, and molecular docking studies</article-title>. <source>J. Biomed .Sci.</source><year>2011</year>, <volume>18</volume>, <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1186/1423-0127-18-8</pub-id>.<pub-id pub-id-type="pmid">21208456</pub-id></mixed-citation>
    </ref>
    <ref id="ref68">
      <mixed-citation publication-type="journal" id="cit68"><name><surname>Zou</surname><given-names>J.</given-names></name>; <name><surname>Xie</surname><given-names>H.-Z.</given-names></name>; <name><surname>Yang</surname><given-names>S.-Y.</given-names></name>; <name><surname>Chen</surname><given-names>J.-J.</given-names></name>; <name><surname>Ren</surname><given-names>J.-X.</given-names></name>; <name><surname>Wei</surname><given-names>Y.-Q.</given-names></name><article-title>Towards more accurate
pharmacophore modeling: Multicomplex-based
comprehensive pharmacophore map and most-frequent-feature pharmacophore
model of CDK2</article-title>. <source>J. Mol. Graphics Modell.</source><year>2008</year>, <volume>27</volume>, <fpage>430</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2008.07.004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref69">
      <mixed-citation publication-type="journal" id="cit69"><name><surname>Wolber</surname><given-names>G.</given-names></name>; <name><surname>Seidel</surname><given-names>T.</given-names></name>; <name><surname>Bendix</surname><given-names>F.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name><article-title>Molecule-pharmacophore
superpositioning and pattern matching in computational drug design</article-title>. <source>Drug Discovery Today</source><year>2008</year>, <volume>13</volume>, <fpage>23</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2007.09.007</pub-id>.<pub-id pub-id-type="pmid">18190860</pub-id></mixed-citation>
    </ref>
    <ref id="ref70">
      <mixed-citation publication-type="journal" id="cit70"><name><surname>Richmond</surname><given-names>N. J.</given-names></name>; <name><surname>Abrams</surname><given-names>C. A.</given-names></name>; <name><surname>Wolohan</surname><given-names>P. R. N.</given-names></name>; <name><surname>Abrahamian</surname><given-names>E.</given-names></name>; <name><surname>Willett</surname><given-names>P.</given-names></name>; <name><surname>Clark</surname><given-names>R. D.</given-names></name><article-title>GALAHAD: 1. Pharmacophore
identification
by hypermolecular alignment of ligands in 3D</article-title>. <source>J. Comput.-Aided Mol. Des.</source><year>2006</year>, <volume>20</volume>, <fpage>567</fpage>–<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-006-9082-y</pub-id>.<pub-id pub-id-type="pmid">17051338</pub-id></mixed-citation>
    </ref>
    <ref id="ref71">
      <mixed-citation publication-type="undeclared" id="cit71"><person-group person-group-type="allauthors"><name><surname>Douguet</surname><given-names>D.</given-names></name>; <name><surname>Payan</surname><given-names>F.</given-names></name></person-group><article-title>SENSAAS (SENsitive Surface
As A Shape): utilizing open-source algorithms for 3D point cloud alignment
of molecules</article-title>. <source>arXiv preprint arXiv:1908.11267</source><year>2019</year>.</mixed-citation>
    </ref>
    <ref id="ref72">
      <mixed-citation publication-type="journal" id="cit72"><name><surname>Eguida</surname><given-names>M.</given-names></name>; <name><surname>Rognan</surname><given-names>D.</given-names></name><article-title>A computer vision approach
to align and compare protein
cavities: application to fragment-based drug design</article-title>. <source>J. Med. Chem.</source><year>2020</year>, <volume>63</volume>, <fpage>7127</fpage>–<lpage>7142</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00422</pub-id>.<pub-id pub-id-type="pmid">32496770</pub-id></mixed-citation>
    </ref>
    <ref id="ref73">
      <mixed-citation publication-type="book" id="cit73"><person-group person-group-type="allauthors"><name><surname>Bertolazzi</surname><given-names>P.</given-names></name>; <name><surname>Liuzzi</surname><given-names>G.</given-names></name>; <name><surname>Guerra</surname><given-names>C.</given-names></name></person-group> In <article-title>A global optimization algorithm for protein surface alignment</article-title><italic>.</italic><source>2009 IEEE International Conference on
Bioinformatics and Biomedicine Workshop</source>; <publisher-name>IEEE</publisher-name>: <year>2009</year>; pp. <fpage>93</fpage>–<lpage>100</lpage>.</mixed-citation>
    </ref>
    <ref id="ref74">
      <mixed-citation publication-type="book" id="cit74"><person-group person-group-type="allauthors"><name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Belaton</surname><given-names>B.</given-names></name></person-group> In <article-title>An improved
iterative closest point algorithm for rigid point registration</article-title><italic>.</italic><source>International Conference on Machine Learning
and Cybernetics</source>; <publisher-name>Springer</publisher-name>: <year>2014</year>; pp. <fpage>255</fpage>–<lpage>263</lpage>.</mixed-citation>
    </ref>
    <ref id="ref75">
      <mixed-citation publication-type="journal" id="cit75"><name><surname>Kabsch</surname><given-names>W.</given-names></name><article-title>Automatic
processing of rotation diffraction data from crystals of initially
unknown symmetry and cell constants</article-title>. <source>J. Appl.
Crystallogr.</source><year>1993</year>, <volume>26</volume>, <fpage>795</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1107/S0021889893005588</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref76">
      <mixed-citation publication-type="journal" id="cit76"><name><surname>Wolber</surname><given-names>G.</given-names></name>; <name><surname>Dornhofer</surname><given-names>A. A.</given-names></name>; <name><surname>Langer</surname><given-names>T.</given-names></name><article-title>Efficient overlay of small organic
molecules using 3D pharmacophores</article-title>. <source>J. Comput.-Aided
Mol. Des.</source><year>2007</year>, <volume>20</volume>, <fpage>773</fpage>–<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-006-9078-7</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref77">
      <mixed-citation publication-type="book" id="cit77"><person-group person-group-type="allauthors"><name><surname>Agarwal</surname><given-names>S.</given-names></name>; <name><surname>Sharma</surname><given-names>I.</given-names></name>; <name><surname>Varma</surname><given-names>D.
A.</given-names></name>; <name><surname>Raj</surname><given-names>A. N.
J.</given-names></name></person-group> In <article-title>A hybrid [ICP
and GA] image registration algorithm for depth images</article-title><italic>.</italic><source>2014 International Conference on Smart
Structures and Systems (ICSSS)</source>; <publisher-name>IEEE</publisher-name>: <year>2014</year>; pp. <fpage>8</fpage>–<lpage>14</lpage>.</mixed-citation>
    </ref>
    <ref id="ref78">
      <mixed-citation publication-type="book" id="cit78"><person-group person-group-type="allauthors"><name><surname>Torres</surname><given-names>D.</given-names></name>; <name><surname>Cuevas</surname><given-names>F.</given-names></name></person-group> In <source>Three-dimensional
Point-cloud Registration using a Genetic Algorithm and the Iterative
Closest Point Algorithm</source><italic>;</italic><publisher-name>IJCCI (ECTA-FCTA)</publisher-name>, <year>2011</year>; pp. <fpage>547</fpage>–<lpage>552</lpage>.</mixed-citation>
    </ref>
    <ref id="ref79">
      <mixed-citation publication-type="journal" id="cit79"><name><surname>Jones</surname><given-names>G.</given-names></name>; <name><surname>Willett</surname><given-names>P.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name><article-title>A genetic algorithm for flexible
molecular overlay and pharmacophore elucidation</article-title>. <source>J. Comput.-Aided Mol. Des.</source><year>1995</year>, <volume>9</volume>, <fpage>532</fpage>–<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1007/BF00124324</pub-id>.<pub-id pub-id-type="pmid">8789195</pub-id></mixed-citation>
    </ref>
    <ref id="ref80">
      <mixed-citation publication-type="journal" id="cit80"><name><surname>Holland</surname><given-names>J. H.</given-names></name><article-title>Genetic
algorithms</article-title>. <source>Sci. Am.</source><year>1992</year>, <volume>267</volume>, <fpage>66</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/scientificamerican0792-66</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref81">
      <mixed-citation publication-type="journal" id="cit81"><name><surname>Trott</surname><given-names>O.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name><article-title>AutoDock Vina: improving
the speed and accuracy of
docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J. Comput. Chem.</source><year>2009</year>, <volume>31</volume>, <fpage>455</fpage>–<lpage>461</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
